Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -12.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -12.44% | |||
| Cost of Revenue | 4.80% | -23.36% | |||
| Gross Profit | -4.99% | 23.73% | |||
| SG&A Expenses | 7.29% | -9.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.80% | -18.41% | |||
| Operating Income | -5.93% | 18.53% | |||
| Income Before Tax | 12.97% | 22.15% | |||
| Income Tax Expenses | -50.00% | -33.33% | |||
| Earnings from Continuing Operations | 12.99% | 22.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.99% | 22.15% | |||
| EBIT | -5.93% | 18.53% | |||
| EBITDA | -6.04% | 18.59% | |||
| EPS Basic | 15.15% | 22.44% | |||
| Normalized Basic EPS | -2.10% | 18.24% | |||
| EPS Diluted | 15.15% | 22.44% | |||
| Normalized Diluted EPS | -2.10% | 18.24% | |||
| Average Basic Shares Outstanding | 2.54% | 0.38% | |||
| Average Diluted Shares Outstanding | 2.54% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||